Testing for KRAS Exon 2 Codon 12 and 13 Somatic Mutations in Colorectal Cancer using the Qiagen KRAS RCG PCR Kit

KRAS Codon 12 and 13 Mutations in Gastric Cancer in the Northeast Iran

Background & objective: KRAS mutations are reported in many types of cancers including pancreas, lung, colon, breast, and gastric (GC). High frequency of KRAS mutation is observed in the pancreas, colon, and lung cancers; they commonly arise in codon 12 and 13 of exon 2. Due to the lack of information about the frequency of KRAS</...

Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF-wild-type Colorectal Cancers Running title: KRAS Codon 12 and Codon 13 Mutations in Colorectal Cancer

1 Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; 2 Molecular Pathology Unit and Center for Cancer Research, Massachusetts General Hospital, Charlestown, MA; 3 Channing Laboratory, Department of Medicine, Brigham and Women’s Hospital, and Harvard Medical School, Boston, MA; 4 Department of Pathology, Brigham and Women’s Hospital, and Harvard ...

SensiScreen® KRAS exon 2-sensitive simplex and multiplex real-time PCR-based assays for detection of KRAS exon 2 mutations

Activating mutations in codon 12 and codon 13 of the KRAS (Kirsten rat sarcoma viral oncogene homolog) gene are implicated in the development of several human cancer types and influence their clinical evaluation, treatment and prognosis. Numerous different methods for KRAS genotyping are currently available displaying a wide range of sensitivities, time to answer and requirements for laboratory...

mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients

KRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis

Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of...